211 related articles for article (PubMed ID: 21120579)
1. Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway.
Lee CS; Jang ER; Kim YJ; Myung SC; Kim W; Lee MW
Invest New Drugs; 2012 Apr; 30(2):548-57. PubMed ID: 21120579
[TBL] [Abstract][Full Text] [Related]
2. 18β-glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathway.
Yang JC; Myung SC; Kim W; Lee CS
Mol Cell Biochem; 2012 Nov; 370(1-2):209-19. PubMed ID: 22865487
[TBL] [Abstract][Full Text] [Related]
3. Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins.
Kim YJ; Lee SA; Myung SC; Kim W; Lee CS
Mol Cell Biochem; 2012 Jan; 359(1-2):33-43. PubMed ID: 21800052
[TBL] [Abstract][Full Text] [Related]
4. Guanylate cyclase activator YC-1 enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells via activation of apoptosis-related proteins.
Lee CS; Kim YJ; Kim W; Myung SC
Basic Clin Pharmacol Toxicol; 2011 Oct; 109(4):283-91. PubMed ID: 21554547
[TBL] [Abstract][Full Text] [Related]
5. Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Lee CS; Kwak SW; Kim YJ; Lee SA; Park ES; Myung SC; Kim W; Lee MS; Lee JJ
Eur J Pharmacol; 2012 May; 683(1-3):54-62. PubMed ID: 22465181
[TBL] [Abstract][Full Text] [Related]
6. Combined effect of Hsp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells.
Lee CS; Kim YJ; Lee SA; Myung SC; Kim W
Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):173-81. PubMed ID: 22433057
[TBL] [Abstract][Full Text] [Related]
7. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.
Farrand L; Kim JY; Byun S; Im-aram A; Lee J; Suh JY; Lee KW; Lee HJ; Tsang BK
J Biol Chem; 2014 Jan; 289(3):1723-31. PubMed ID: 24247248
[TBL] [Abstract][Full Text] [Related]
8. 18β-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
Lee CS; Yang JC; Kim YJ; Jang ER; Kim W; Myung SC
Eur J Pharmacol; 2010 Dec; 649(1-3):354-61. PubMed ID: 20868669
[TBL] [Abstract][Full Text] [Related]
9. Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines.
Jang ER; Kim YJ; Myung SC; Kim W; Lee CS
Mol Cell Biochem; 2011 Jul; 353(1-2):1-11. PubMed ID: 21380726
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.
Naumann I; Kappler R; von Schweinitz D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3204-18. PubMed ID: 21459798
[TBL] [Abstract][Full Text] [Related]
11. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
12. Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y; Tian B; Wang Y; Ding H
Med Sci Monit; 2017 Oct; 23():5096-5105. PubMed ID: 29070784
[TBL] [Abstract][Full Text] [Related]
13. TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells.
Jin CY; Molagoda IMN; Karunarathne WAHM; Kang SH; Park C; Kim GY; Choi YH
Toxicol Appl Pharmacol; 2018 Aug; 352():132-141. PubMed ID: 29792947
[TBL] [Abstract][Full Text] [Related]
14. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
15. Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines.
Lee SJ; Kim YJ; Lee CS; Bae J
Chem Biol Interact; 2009 Oct; 181(2):185-92. PubMed ID: 19481069
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
17. (E)-2,4-Bis(p-hydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NF-κB/STAT3 pathway.
Cho SH; Park MH; Lee HP; Back MK; Sung HC; Chang HW; Kim JH; Jeong HS; Han SB; Hong JT
Arch Pharm Res; 2014 May; 37(5):652-61. PubMed ID: 24390815
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
19. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
Wahl H; Tan L; Griffith K; Choi M; Liu JR
Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
